125 results about "Helicobacter" patented technology

The invention discloses a compound microbial agent for reducing the cadmium content of brown rice and application of the compound microbial agent. Belongs to the technical field of agricultural microorganisms. The compound microbial agent is prepared from herbaceous spirillum, stenotrophomonas and coxakia, the herbaceous spirillum is herbaceous spirillum R3, and the preservation number of the herbaceous spirillum is CCTCC (China Center For Type Culture Collection) NO: M 20231757; the stenotrophomonas is stenotrophomonas R5, and the preservation number of the stenotrophomonas is CCTCC (China Center For Type Culture Collection) NO: M 20231758; the coxakia is coxakia P1-4, and the preservation number of the coxakia is CCTCC (China Center For Type Culture Collection) NO: M 20231759. Compared with the prior art, the compound microbial agent disclosed by the invention has the beneficial effects that the compound microbial agent disclosed by the invention can reduce the content of cadmium in brown rice, so that farmland soil polluted by light and medium cadmium can be repaired and produced at the same time, and the edible safety of agricultural product rice is ensured.

The invention belongs to the technical field of probiotic preparations, and particularly relates to bifidobacterium longum subsp. Longum and application thereof in resisting helicobacter pylori. The bifidobacterium longum subsp. Longum provided by the invention has a good inhibition effect on helicobacter pylori. Furthermore, the bifidobacterium longum subsp. Longum is effectively embedded through enzyme cross-linking and ionic cross-linking by adopting the bifidobacterium longum subsp. Longum, so that not only can the embedding rate of the strain be improved, but also the survival rate of the strain can be remarkably improved in a digestion environment, and the efficient planting of the strain is realized; particularly, the effect of resisting helicobacter pylori infection can be obviously improved. Therefore, the invention has important practical significance on prevention and treatment of helicobacter pylori infection, and can also provide a technical basis for application of anti-helicobacter pylori functional products in the future.

The invention provides a probiotic composition for preventing and / or inhibiting oral pathogens as well as a derivative product, a preparation method and application of the probiotic composition, and belongs to the technical field of oral care. The probiotic composition comprises the following bacterial strains in parts by mass: 90 to 0.45 part of a lactobacillus rhamnosus bacterial strain A2114, 10 to 0.3 part of a plant lactobacillus bacterial strain A2124, 80 to 0.4 part of a pediococcus pentosaceus bacterial strain A2135, 250 to 0.25 part of a lactobacillus reuteri bacterial strain A21350, and 40 to 0.2 part of a plant lactobacillus bacterial strain A2109. The probiotic composition or the metabolite thereof can effectively inhibit oral pathogens such as streptococcus mutans, porphyromonas gingivalis, helicobacter pylori, escherichia coli and staphylococcus aureus. Therefore, the probiotic composition or the metabolite thereof shows a good application prospect in the aspects of preventing and relieving oral problems such as decayed teeth, periodontitis and ozostomia.

The invention relates to the field of microorganisms, in particular to lactobacillus plantarum TRT-01 with anti-inflammatory and bacteriostatic functions as well as a preparation method and application of the lactobacillus plantarum TRT-01, the lactobacillus plantarum TRT-01 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.32237, and the preservation date is October 17, 2024. The plant lactobacillus has broad-spectrum bacteriostatic activity on 10 pathogenic bacteria such as helicobacter pylori, streptococcus mutans and the like, and can regulate Th1 / Treg immune balance and relieve inflammatory response by inducing dendritic cells to secrete cell factors IL-10 and IL-12, inducing T cells to secrete cell factors TGF-beta and IFN-gamma and inhibiting secretion of cell factors IL-6 at the same time. Therefore, the plant lactobacillus TRT-01 disclosed by the invention can be used for preparing a composition with anti-inflammatory and bacteriostatic effects, is suitable for the fields of medicines, foods, health-care products and the like, and is particularly suitable for developing a microbial preparation with a probiotic effect.

The invention discloses a hydrogel-based helicobacter pylori killing medicine and a preparation method thereof in the technical field of biomedical materials, and the hydrogel medicine adopts a shell-core layered structure and comprises an outer layer and an inner layer; the outer layer is a high-density cross-linked polyethylene glycol diacrylate network, and cellulose nanocrystals modified by silane are dispersed in the polyethylene glycol diacrylate network; pH-sensitive Schiff base bonds and / or boric acid ester bonds are embedded in the inner layer, and an antibacterial agent is loaded on the inner layer. Structural expansion and breaking of the hydrogel are controlled through a multi-layer structure, multiple loaded antibacterial agents are released according to pH response, the influence of drug resistance is avoided through sterilization of multiple mechanisms, the preparation process and device of the hydrogel drug are integrated, the production cost is reduced, and the clinical conversion efficiency is guaranteed.

The invention belongs to the technical field of synthesis, and particularly relates to a synthesis method of urea [14C]. The synthesis method of the urea [14C] comprises the following steps: (1) reacting carbonate [14C] with ammonia gas to obtain cyanamide salt [14C]; (2) hydrolyzing the cyanamide salt [14C] obtained in the step (1) with concentrated sulfuric acid at the hydrolysis temperature of 35-45 DEG C; and (3) adjusting the pH value of the hydrolysate obtained in the step (2) with ammonia water, concentrating and purifying to obtain urea [14C]. The synthesis method provided by the invention has the advantages of mild conditions, efficient reaction, high product yield (up to 95% or above), high purity (the chemical purity is greater than or equal to 99%) and the like, and is suitable for large-scale preparation of key raw materials of helicobacter pylori diagnostic reagents.

The invention provides a probiotic composition for inhibiting helicobacter pylori as well as a probiotic agent and application thereof, and belongs to the technical field of probiotic functional products. The probiotic composition is prepared from the following components in parts by weight: 0.05 to 2 parts of a pediococcus pentosaceus strain A21358, 0.01 to 1.5 parts of a plant lactobacillus strain A21136, 0.05 to 1.5 parts of a lactobacillus rhamnosus strain A21149 and 0.03 to 1.2 parts of a lactobacillus reuteri strain A21325. The probiotic agent comprises the probiotic composition, resistant dextrin, xylooligosaccharide, erythritol, inulin, fructo-oligosaccharide, hericium erinaceus powder, fucoidin and at least one fruit powder selected from grape powder, passion fruit powder and kiwi fruit powder, wherein the specific weight parts of the resistant dextrin, the xylooligosaccharide, the erythritol, the inulin, the fructo-oligosaccharide, the hericium erinaceus powder, the fucoidin and the at least one fruit powder are selected from grape powder, passion fruit powder and kiwi fruit powder. The probiotic agent has the effect of inhibiting helicobacter pylori, and a new thought is provided for clinical related auxiliary treatment of helicobacter pylori infection.

The invention relates to a nano bismuth agent for preventing and / or treating gastritis infection as well as a preparation method and application thereof, the preparation method comprises the following steps: respectively dissolving soluble bismuth salt and a sulfur-containing compound, mixing, and reacting to obtain the nano bismuth agent after the reaction is finished, the sulfur-containing compound is any one or a combination of at least two of thioamino acid, vitamin B1, thioacetamide, sodium sulfide, sodium thiosulfate, bovine serum albumin, whey protein, ovalbumin or metallothionein. The prepared nano bismuth agent has efficient antibacterial performance, shows an excellent curative effect which is two orders of magnitude higher than that of an existing bismuth complex on clinically separated drug-resistant helicobacter pylori, and does not further induce increase of drug resistance of the helicobacter pylori.

The invention belongs to the field of biological medicine, and particularly relates to an anti-inflammatory and anti-helicobacter pylori compound separated from agilawood and a preparation method thereof. The method comprises the following steps: by taking the agilawood corasta as a raw material, carrying out reflux extraction with ethanol, extracting with petroleum ether to remove volatile components, separating and purifying by adopting various chromatographic technologies such as silica gel column chromatography, reversed-phase column chromatography and semi-preparative HPLC (High Performance Liquid Chromatography) to obtain a monomeric compound, and identifying the structure of the monomeric compound by adopting spectroscopy methods such as ultraviolet, high-resolution mass spectrometry and nuclear magnetic resonance. The structure of a compound 1 is identified as a new 2-(2-phenethyl) chromone dimer, and the compound 1 is named as aquicrasone V. The invention further discloses a preparation method of the compound 1. A biological activity test verifies that the compound has relatively strong anti-inflammatory activity and anti-helicobacter pylori activity.

The invention relates to the technical field of stomach filling agents, and particularly discloses a stomach filling agent and a preparation method thereof. The stomach filling agent is prepared from, by weight, 50-75 parts of composite hydrogel, 1.7-2.8 parts of digestion promoting microcapsules and 0.7-1.2 parts of helicobacter pylori resisting matter, the composite hydrogel is formed by crosslinking sodium alginate and sulfhydrylated fructose-chitosan, the capsule wall of each digestion promoting microcapsule is gelatin and sodium alginate, and the capsule wall of each digestion promoting microcapsule is gelatin and sodium alginate. The core of the digestion promoting microcapsule is chitosanase; in addition, the preparation method disclosed by the invention has the advantages of reducing the stimulation of the gastric filling agent to gastric mucosa and improving the multifunctionality of the gastric filling agent.

The invention provides an innovative dual-mode detection method based on a dipeptide nano framework (DNPs), which is used for efficiently detecting helicobacter pylori. According to the method, firstly, a DNPs material formed by chelating dipeptide (Trp-Phe) and zinc ions (Zn (II)) is synthesized, and the material is decomposed along with the increase of the pH value in an alkaline environment, so that the Zn (II) is released; then, urea is hydrolyzed under the catalysis of urease to generate ammonia, so that the pH value of the solution is increased, and the decomposition of DNPs and the release of Zn (II) are further promoted. By utilizing an electrochemical detection mode, real-time analysis on urea and urease is realized by monitoring an electrochemical signal of Zn (II); meanwhile, in combination with the fluorescence characteristics of DNPs, the concentration of urea and urease is indirectly and quantitatively analyzed by monitoring the fluorescence intensity change. The dual-mode detection method combines the advantages of electrochemistry and fluorescence detection, has high sensitivity and real-time performance, provides an effective means for accurate detection of helicobacter pylori, and shows a wide application prospect in clinical diagnosis and sensing technologies.

The application provides a human Helicobacter pylori detection method and kit based on the nature of four-strand DNA oxidoreductase. The method uses isothermal amplification technology, amplifies the genomic fragment containing the four-strand DNA sequence in the human Helicobacter pylori genome, and realizes rapid and visual detection of the human Helicobacter pylori by adding hematin and oxidoreductase substrate for color reaction.

The application discloses a degradable gemini morpholine quaternary ammonium salt. The application further discloses a preparation method of the degradable gemini morpholine quaternary ammonium salt, comprising the following steps: S1, performing N-alkylation reaction on morpholine and halogenated alkane to obtain N-alkyl morpholine; S2, performing reaction on substance A and halogenated acetyl halide to obtain substance B; S3, continuously performing N-alkylation reaction on the N-alkyl morpholine and the substance B to obtain the degradable gemini morpholine quaternary ammonium salt. The application further discloses application of the degradable gemini morpholine quaternary ammonium salt in a bactericide and in preparation of a medicine for treating helicobacter pylori infection. The gemini morpholine quaternary ammonium salt has a good effect of killing helicobacter pylori; the gemini morpholine quaternary ammonium salt can be degraded in an alkaline environment, can avoid drug resistance of helicobacter pylori to the gemini morpholine quaternary ammonium salt, and can make the degradation product be rapidly discharged out of the body.

The invention belongs to the field of traditional Chinese medicines, and provides application of a watermelon frost and periplaneta americana composition in preparation of a medicine for treating gastric ulcer caused by helicobacter pylori. The invention provides an application of a mirabilitum praeparatum and periplaneta americana composition in treatment of gastric ulcer, the composition has an effect of inhibiting and killing helicobacter pylori in vitro, and has a good synergistic effect in a specific proportion; the composition can reduce the ulcer index of a gastric ulcer model rat, and has good effects of protecting gastric mucosa and improving gastric ulcer; compared with a control Chinese patent medicine, the medicament prepared from the composition can improve the effective rate of helicobacter pylori induced gastric ulcer and the HP eradication rate. The invention provides a novel pharmaceutical composition for helicobacter pylori induced gastric ulcer, and the pharmaceutical composition is high in safety and few in side effect.

The present application relates to the technical field of Raman spectrum detection, and in particular to a stomach H. pylori infection detection method based on Raman spectrum. The method performs Raman spectrum detection on a gastric juice sample to obtain a Raman spectrum curve; a healthy Raman spectrum curve of a healthy gastric juice sample is obtained and constructed into a healthy sample spectrum library; according to the Raman intensity difference and waveform distribution similarity of each healthy Raman spectrum curve in the healthy sample spectrum library with other healthy Raman spectrum curves in a specified wavelength range, a representative weight of each healthy Raman spectrum curve is obtained; according to the Raman intensity distribution similarity of the Raman spectrum curve of the current patient with each healthy Raman spectrum curve in the specified wavelength range and the representative weight of each healthy Raman spectrum curve, the infection degree of the current patient is obtained, and it is determined whether the current patient is infected with H. pylori. The present application effectively improves the preparedness and universality of H. pylori detection by obtaining the infection degree.

This invention belongs to the field of probiotic technology, specifically relating to a probiotic for combating Helicobacter pylori infection and its application. The probiotic is Limosilactobacillus reuteri ZKAW05, derived from Tibetan yak milk residue, with the preservation number GDMCC NO: 65682. This probiotic exhibits good acid resistance, bile salt resistance, and Helicobacter pylori inhibition. After being cultured in an inducible culture medium, it is used to prepare probiotic powders, capsules, or tablets for combating Helicobacter pylori infection. It can maintain good probiotic activity in the gastrointestinal tract and is used to prevent or alleviate Helicobacter pylori infection in the oral cavity, gastrointestinal tract, and other sites.

The invention discloses a method and device for identifying helicobacter pylori based on artificial intelligence fluorescence imaging, and relates to the technical field of artificial intelligence medical detection. Comprising the following steps: S1, carrying out slide preparation treatment on a cytological sample or a tissue slice sample, and processing the slide preparation through an immunofluorescent staining reagent to obtain a helicobacter pylori fluorescent staining picture; s2, outputting and obtaining a helicobacter pylori picture with a rectangular frame identifier through a helicobacter pylori identifier neural network model; and S3, according to the coordinate information of the rectangular frame, obtaining the coordinate information of the helicobacter pylori in the fluorescent staining picture, and splicing the helicobacter pylori pictures to obtain a spliced picture. According to the method, the helicobacter pylori is marked automatically through the helicobacter pylori identification neural network model, the problems of subjectivity and time consumption of traditional manual microscopic examination are avoided, meanwhile, the positions of thalli are accurately marked, positive probability data are output, and then the detection efficiency is improved.

The embodiment of the present specification provides an antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease, the antibody or antigen binding fragment comprising a heavy chain variable region and a light chain variable region. Wherein, the heavy chain variable region comprises CDRH1 of an amino acid sequence as shown in SEQ ID NO: 2, CDRH2 of an amino acid sequence as shown in SEQ ID NO: 3 and CDRH of an amino acid sequence as shown in SEQ ID NO: 4. The light chain variable region comprises CDRL1 of an amino acid sequence as shown in SEQ ID NO: 6, CDRL2 of an amino acid sequence of DTS and CDRL3 of an amino acid sequence as shown in SEQ ID NO: 7. The antibody or antigen binding fragment has the characteristics of high purity, high specificity and sensitivity. The embodiment of the present specification also provides related application of the antibody or antigen binding fragment binding to Helicobacter pylori antigen protein urease.

The invention relates to the technical field of microorganisms, in particular to a metagen for inhibiting helicobacter pylori infection and a preparation method of the metagen. The metagen is prepared by culturing the plant lactobacillus HYProbio-Y4, the preservation number of the plant lactobacillus HYProbio-Y4 is CGMCC (China General Microbiological Culture Collection Center) No.35968, and the metagen has the capability of inhibiting the activity of helicobacter pylori and urease in vitro; and the urease inhibitor can tolerate extreme temperature and pH, and can maintain high urease inhibition activity under the conditions that the temperature is 37-60 DEG C and the pH is 2-11.

The invention discloses recombinant bacteriophage lyase and application thereof. The amino acid sequence of the recombinant bacteriophage lyase E8-3 is as shown in SEQ ID NO: 43, and an in-vitro minimum inhibitory concentration experiment shows that the recombinant bacteriophage lyase E8-3 has a bacteriostatic effect on helicobacter pylori and acinetobacter baumannii, and particularly has a wide application prospect in the development of anti-helicobacter pylori drugs.

The utility model relates to the technical field of waste gas treatment devices for detectors, in particular to a waste gas treatment device for a helicobacter pylori detector, which is characterized in that inactivated gas is decomposed by starting a decomposition mechanism, and when impurities in a filter plate of a filter mechanism are saturated, a gas supply mechanism is restarted to supply gas to the filter plate of the filter mechanism; a filtering plate of the filtering mechanism is subjected to back flushing cleaning, impurities discharged from the filtering plate of the filtering mechanism are collected and discharged through a second discharging mechanism, and the practicability of the equipment is improved; comprising a supporting mechanism; the device further comprises an air supply mechanism, a filtering mechanism, a decomposing mechanism, a first discharging mechanism and a second discharging mechanism, the air supply mechanism, the filtering mechanism and the decomposing mechanism are all installed in the supporting mechanism, the filtering mechanism is located in the middle of the air supply mechanism, the decomposing mechanism is located on the upper portion of the air supply mechanism, and the first discharging mechanism is installed on the supporting mechanism. The second discharging mechanism is installed in the supporting mechanism and located below the air supply mechanism.

The invention provides an oral care composition for inhibiting helicobacter pylori and a preparation method of the oral care composition. The oral care composition comprises glycerin, xylitol, erythritol, thymol clathrate, garlic extract clathrate, propolis extract, lactoferrin, disodium ethylene diamine tetraacetate, menthol, potassium sorbate and purified water. The thymol clathrate compound is obtained by carrying out clathration on thymol through beta-cyclodextrin. The garlic extract clathrate compound is obtained by clathrating a garlic extract with beta-cyclodextrin. According to the oral care composition provided by the invention, the helicobacter pylori in the oral cavity can be effectively inhibited through reasonable proportioning of various components, so that the risks of ozostomia and stomach reinfection are reduced.

The application discloses application of sea cucumber saponins and / or sea cucumber saponin derivatives in anti-helicobacter pylori products. The application specifically discloses application of sea cucumber total saponins, sea cucumber saponin monomers, disaccharide-removed products of the sea cucumber saponin monomers, tetrasaccharide-removed products of the sea cucumber saponin monomers, and desulfurized products of the sea cucumber saponin monomers in anti-helicobacter pylori products. The application also discloses preparation methods of the sea cucumber total saponins, the sea cucumber saponin monomers, the disaccharide-removed products of the sea cucumber saponin monomers, the tetrasaccharide-removed products of the sea cucumber saponin monomers and the desulfurized products of the sea cucumber saponin monomers.

The invention discloses a degradable gemini morpholine quaternary ammonium salt. The invention also discloses a preparation method of the degradable gemini morpholine quaternary ammonium salt, and the preparation method comprises the following steps: S1, morpholine and halogenated alkane are subjected to an N-alkylation reaction to obtain N-alkyl morpholine; s2, reacting the substance A with halogenated acetyl halide to obtain a substance B; s3, N-alkyl morpholine and the substance B are continuously subjected to an N-alkylation reaction, and the degradable gemini morpholine quaternary ammonium salt is obtained. The invention also discloses application of the degradable dimeric morpholine quaternary ammonium salt as a bactericide in preparation of drugs for treating helicobacter pylori infection. The gemini morpholine quaternary ammonium salt disclosed by the invention has a good effect of killing helicobacter pylori; and the gemini morpholine quaternary ammonium salt can be degraded in an alkaline environment, so that the drug resistance of helicobacter pylori to the gemini morpholine quaternary ammonium salt can be avoided, and the degradation product can be quickly discharged out of the body.

The application relates to the technical field of biological detection, and particularly discloses a rapid detection kit for Helicobacter pylori and an application method thereof; the kit comprises a sample processing liquid, an antigen pre-enrichment particle suspension and an immunochromatography test paper card; the sample processing liquid comprises an antigen-induced release system, a composite lysis system, a matrix interference blocking system and a chromatography promoter; the antigen pre-enrichment particle is a magnetic nanoparticle with an anti-Helicobacter pylori antibody coupled on the surface; and the immunochromatography test paper card is provided with a first detection line, a second detection line and a quality control line on a nitrocellulose membrane in sequence. The antigen is mildly and efficiently released through the antigen-induced release system, the bacterial cell wall is synergistically lysed through non-ionic and anionic surfactants, the interference substance is blocked through a double mechanism of a protein blocking agent and a metal ion chelating agent, the low-abundance antigen is enriched through the magnetic nanoparticle, and the sample effectiveness is monitored through the second detection line.

The invention discloses a broccoli seed extract glucoraphanin pharmaceutical composition and a preparation method thereof, and belongs to the field of pharmaceutical compositions. The method aims at solving the problems that in a traditional extraction method, the glucoraphanin concentration is low, the extraction efficiency is insufficient, and multiple antioxidant and anti-inflammatory components are difficult to be stably compatible due to physical and chemical differences. The composition contains the glucoraphanin extract with the purity larger than or equal to 92%, quercetin, forsythin and other components, the composition is prepared through the processes of microwave-assisted extraction, high-pressure homogenization, macroporous resin purification and the like, and the purity of all the components reaches the high level. Experiments prove that the composition can strongly inhibit helicobacter pylori, has concentration-dependent antioxidant activity, can resist inflammation, is low in side effect and high in safety, realizes multi-target protection such as oxidation resistance, inflammation resistance and the like through cooperation of multiple components, and is suitable for prevention and treatment of related diseases.

The utility model discloses a helicobacter pylori assay kit, including main part, closure mechanism and preservation mechanism, closure mechanism includes closure cover, handle, connecting band, fixture block, spring and seal subassembly, seal subassembly includes rubber pad, seal cover and rotating rod, preservation mechanism includes refrigerator, controller, heat preservation pad and placing box, and the refrigerator includes the refrigerator, controller, heat preservation pad and placing box. Under the mutual matching action of the mechanisms, the quick connection design of the closing cover and the main body is adopted, and the kit can be easily opened and closed, so that a user does not need tedious steps during sampling or detection, the operation is simple and efficient, the kit is still kept in a sealed state after being quickly connected, and the detection efficiency is improved. According to the kit, external air or pollutants are prevented from entering the kit, the quality of internal reagents is protected, in addition, proper internal temperature can be kept before and after detection, the reagents are ensured to be in an optimal storage state all the time, and energy consumption can be reduced due to a built-in temperature adjusting system.

The application provides a use of a nitrothiazole derivative in preparation of an antibacterial agent for inhibiting helicobacter pylori, and belongs to the field of pharmacy.The structure of the amino nitrothiazole derivative is shown as formula I.The experimental results show that the compound can effectively inhibit the growth of helicobacter pylori, and the inhibiting effect is better than that of control compounds nitazoxanide and lauric acid; the compound can effectively treat mice infected with helicobacter pylori, clear helicobacter pylori in the stomach and reduce the inflammatory response of the stomach tissue, and the treatment effect is better than that of control compounds nitazoxanide and lauric acid.The compound provided by the application can be used for preparing the antibacterial agent for inhibiting helicobacter pylori, and can be used for preparing a medicine for preventing and / or treating helicobacter pylori infection and related diseases caused by the helicobacter pylori, and has a wide application prospect.

This application relates to a label-free immunosensor for Helicobacter pylori, its preparation method, and its application. The method involves directly incubating the Helicobacter pylori multivalent epitope antigen FvpE on a modified electrode, eliminating the need for hybridization labeling during the preparation of the label-free immunosensor. This simplifies the preparation process, making it simple and easy to operate. Furthermore, the prepared label-free immunosensor can directly detect Helicobacter pylori in samples, greatly simplifying the detection process and reducing detection time. Simultaneously, the prepared label-free immunosensor can detect polyclonal antibodies anti-Hp and different antibody genotypes such as CagA, UreA, UreB, and VacA, and can simultaneously detect multiple cytotoxins or virulence factors. This improves the universality of the label-free immunosensor, thereby reducing workload, shortening detection time, and lowering detection costs.

Provided is a composition of Arctium lappa and Lithospermum erythrorhizon and a method for preparing same. The composition comprises an A. lappa extract and an L. erythrorhizon extract, wherein the A. lappa extract accounts for 90%-10% of the composition, in percentage by weight; the L. erythrorhizon extract accounts for 10%-90% of the composition, in percentage by weight. The composition can be used for preparing a pharmaceutical composition for preventing or treating peptic ulcer or for resisting Helicobacter pylori.